—An analysis of population-based data revealed that males born with DMD experienced prolonged survival when cardiac medication was initiated while LVF was normal, highlighting an area of focus for ...

CureDuchenne, a global leader in funding and advancing research for Duchenne muscular dystrophy, today announced a second investment into Tevard Biosciences to support the advancement of the company's ...

A regularly prescribed class of heart medications might be capable of treating one of the most common forms of muscular dystrophy, a new study in mice suggests. Myotonic dystrophy type 1 (DM1) is ...

Consensus directed medical therapy (CDMT) was used in 73.1% of DMD patients with moderate or severe left ventricular dysfunction, leaving nearly 30% without recommended treatment. Target doses were ...

About one in every 3,500-5,000 boys worldwide is born with Duchenne Muscular Dystrophy, or DMD, a rare genetic condition that ...

Georgian Health Minister Mikheil Sarjveladze said decisions regarding medications for the treatment of Duchenne muscular ...

Experts discuss the landscape of treatment options for Duchenne muscular dystrophy, examine the benefits and risks of gene therapy and conventional steroid treatments, and emphasize the need for early ...

The U.S. Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of muscular dystrophy to be used in most people who have the disease and a certain ...

DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Duchenne Muscular ...

Georgian Prime Minister Irakli Kobakhidze said that decisions regarding the financing of medication for children with ...

A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1 -- the most prevalent form of adult-onset muscular dystrophy -- provides insight into why patients develop fatty liver ...